Early-Phase IND Protocol Recommendations for Solid Tumors; Draft Guidance for Industry; Availability
By Drug Administration, Human Services Department, Food, Health · Nov 11, 2026, 11:00 PM CST
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry titled "Early-Phase IND Protocol Recommendations for Solid Tumors." The purpose of this draft guidance is to provide recommendations to sponsors and clinical investigators developing early-phase trials, which include first-in- human (FIH) protocols or protocols for drugs and biologic pr
Excerpt shown under fair-use limits. Full text remains with the original publisher.
People in this coverage
Explore their history and attributable record. Being mentioned does not imply endorsement.
Layer 1 · Claims & fact checks
AI analysisLayer 3 · Reporting analysis
AI analysisOfficial announcementThe language is formal and authoritative, typical of a regulatory agency communicating a new policy document.
Scope clarificationThe statement delineates the boundaries of the guidance, limiting its applicability and preemptively addressing potential misunderstandings.
Context
AI analysisMissing context
The announcement does not explain how the draft guidance will affect ongoing or future trial designs, the timeline for public comment, or any potential regulatory implications for sponsors.
Important context
The guidance is a draft, meaning it is open for public comment before finalization, and it is limited to solid‑tumor indications, excluding hematologic malignancies.
Opinion vs. reporting
AI analysisThe text is purely factual reporting of an FDA announcement; it contains no opinion or editorial commentary.